29 C
Vientiane
Thursday, June 19, 2025
spot_img
Home Blog Page 860

Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States

  • Hanmi Pharmaceutical Global Business Headquarters Accelerates Expansion into Canadian and US Markets, Strengthening Collaboration with Distribution Partner McKesson
  • Introducing ‘Countmate’: A Customized Solution for Canadian and American Pharmacists Seeking Advanced Vial Preparation Technology

SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ — Hanmi Pharmaceutical’s Global Business Headquarters Overseas Sales Team is making significant strides in penetrating the Canadian and US markets with innovative products developed by its affiliate, JVM Co., Ltd. (054950.KQ).

Hanmi Pharmaceutical and McKesson Automation representatives pose for a commemorative photo at the ASHP 2024 exhibition in New Orleans, USA. Pictured from left: McK Kevin Cloutier (Vice President of Sales & Business Development, McKesson Pharmacy Automation, USA), Yves Blanchette (Vice President of Technology Solutions, McKesson Canada), Hanmi Pharmaceutical Overseas Sales Team Leader Lee Ji-hyun, and McK Steve Dennison (Vice President and General Manager, McKesson Canada Automation).
Hanmi Pharmaceutical and McKesson Automation representatives pose for a commemorative photo at the ASHP 2024 exhibition in New Orleans, USA. Pictured from left: McK Kevin Cloutier (Vice President of Sales & Business Development, McKesson Pharmacy Automation, USA), Yves Blanchette (Vice President of Technology Solutions, McKesson Canada), Hanmi Pharmaceutical Overseas Sales Team Leader Lee Ji-hyun, and McK Steve Dennison (Vice President and General Manager, McKesson Canada Automation).

Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park) announced on February 14 that it recently unveiled Countmate, a fully automated vial dispensing machine tailored to the unique preferences of the Canada and US market. Unlike Korea, where medications are commonly dispensed in pouch form, the pharmaceutical industry in Canada and US predominantly relies on the vial method, which involves packaging drugs in plastic bottles. With the launch of Countmate, Hanmi aims to strengthen its presence in the region and drive significant growth in its global sales.

Countmate streamlines the entire dispensing process — from drug counting and dispensing to labeling, image verification, and final vial discharge — within a fully automated system. Hanmi Pharmaceutical highlighted that this launch marks a significant expansion of JVM’s product lineup, which had previously been centered on pouch-type dispensing equipment. “By adding vial dispensing capabilities with Countmate, we anticipate substantial growth in our global sales, particularly in Canada and US“, the company stated.

To ensure a successful market entry, Hanmi Pharmaceutical worked closely with McKesson Automation (McK), the Canada and US distributor for JVM and a key partner in the region. Countmate was officially introduced to the public at the ASHP (American Society of Health-System Pharmacists) Midyear 2024 Conference, held in New Orleans, USA, from December 9 to 12 last year.

The ASHP Midyear Conference is the largest gathering of pharmacy professionals in the United States, hosting an annual event where industry experts convene to discuss key topics such as medication management, regulatory compliance, and pharmacy optimization.

Countmate is designed with cutting-edge technology to revolutionize pharmacy operations. It integrates multiple front-mounted canisters for automatic drug counting, an orthogonal robot for precise vial labeling, and seamless image verification before discharge.

Configurable with 84 or 168 canisters based on pharmacy size and needs, the system can process up to 160 prescriptions per hour, ensuring high efficiency for busy operations.

The machine also enhances quality control with built-in cameras that capture top and side images of each vial, ensuring thorough verification. Additional features that support operational efficiency include: automatic vial sorting and supply, automated label attachment, patient-specific vial discharge sorting, and one sided operation design to maximize the pharmacy space efficiency with low-noise operation.

Beyond its technical sophistication, Countmate prioritizes safety and user convenience. Key benefits include: Safety sensors to prevent accidents by detecting human presence during operation, hygienic preparation processes for contamination-free vial handling, and a compact, space-efficient design adaptable to various pharmacy layouts for seamless installation and operation.

Hanmi anticipates that Countmate’s advanced functionality and competitive pricing will make it an attractive option for pharmacies introducing automated equipment for the first time.

The development of Countmate was achieved through close collaboration between Hanmi and JVM, with a focus on optimizing its design by analyzing and adapting to the unique pharmaceutical formulation patterns of the Canadian and the US markets. Furthermore, Hanmi continues to maintain a strong partnership with McKesson to ensure the product’s successful launch and sustained growth in the region.

A representative of Hanmi Pharmaceutical’s Global Business Division stated that Countmate embodies innovative technology designed to meet the unique needs of the Canadian and the US market. He credited the product’s success to the synergy between Hanmi and JVM’s technological expertise and McKesson’s deep market knowledge and extensive network.

Hanmi Pharmaceutical CEO Park Jae-hyun remarked, “Moving forward, Hanmi will actively pursue business opportunities that create synergy across the entire group. We are committed to expanding our global footprint and will make every effort to further increase the overseas share of our total sales.”

See the Future with Luck: VISTA Eye Specialist Promotes Eye Health with CNY Eye Carnival Nationwide

PETALING JAYA, Malaysia, Feb. 14, 2025 /PRNewswire/ — As people live longer, ensuring a purposeful and fulfilling life becomes even more important. Life expectancy in Malaysia has steadily increased to 76.26 years ([1]), highlighting the growing need for proactive healthcare. Clear vision is crucial for maintaining independence, quality of life, and achieving personal aspirations. In response, VISTA Eye Specialist (VISTA) proudly presents the VISTA CNY Eye Carnival—a nationwide initiative to raise awareness about preventable blindness and the importance of regular eye screenings.

VISTA Eye Specialist's CNY Eye Carnival is happening over two exciting weekends.
VISTA Eye Specialist’s CNY Eye Carnival is happening over two exciting weekends.

Preventable Blindness: Early Detection Saves Vision

Vision loss is not an inevitable part of aging—many leading causes of blindness can be prevented with early detection and timely treatment. VISTA highlights the top three preventable causes of blindness:

Cataracts – The most common cause of blindness in Malaysia, responsible for 58.6% of cases ([2]). Modern cataract surgery can restore vision, but early detection is key.

Glaucoma – Known as the silent thief of sight, this disease damages the optic nerve with little to no symptoms until significant vision is lost. Regular screenings help detect it early and prevent irreversible blindness.

Diabetic Retinopathy – A serious eye complication from diabetes that affects 44.1% to 48.6% of diabetic patients in Malaysia ([3]). Without treatment, it can lead to blindness. Diabetes is a growing public health concern, affecting 20% of adults, with cases increasing from 11.2% in 2011 to 18.3% in 2019 ([4]).

The solution? Early detection and annual eye screenings! Malaysians over 50 should get their eyes checked every year. ([5]).

A Meaningful Celebration at the VISTA CNY Eye Carnival

Chinese New Year is a time of family reunions, togetherness, and celebration. Family gatherings highlight the importance of seeing loved ones clearly, a fundamental part of Ikigai—the Japanese philosophy of finding joy and purpose in life. Through this event, VISTA aims to encourage Malaysians to cherish their vision and take proactive steps toward maintaining eye health.

With the theme 年年有Luck (Nian Nian You Luck), Wish U-Luck Eye Carnival”, this event is part of VISTA’s Environmental, Social, and Governance (ESG) efforts to improve public health while engaging the community in a meaningful way to celebrate eye health, family connections, and prosperity across Malaysia.

“The VISTA CNY Eye Carnival has been six months in the making, and we are excited to share this initiative with the public in our centers nationwide. Our goal is to blend fun with education, so families and children leave with wonderful memories and greater awareness about the importance of eye health,” says Adrian Lim, Project Leader of the Carnival.

Exciting Activities Await!

  • Interactive carnival booths – Experience fun games and eye health challenges!
  • Family Connection Focus – Strengthening bonds through interactive activities emphasizing well-being and togetherness.
  • VISTA Diner – The Jellycat Experience – A playful, heartwarming experience bringing extra interactive fun.
  • Carnival giveaways – Receive Longevity Noodles, kids’ favorite stationery, and exclusive prizes!
  • Birthday Bash surprises – Celebrate February birthdays with a special hand towel gift!
  • Spend & Spin promotions – Stand a chance to win mystery gifts, travel accessories, and home essentials!
  • Social Media Giveaway – Win a Jellycat Little Snake plush (as seen with ENHYPEN), Touch ‘n Go reload pins, travel essentials, thrilling experiences, and a must-have home coffee upgrade.

VISTA’s Commitment to Eye Health & ESG Initiatives

Beyond eye care, VISTA integrates Environmental, Social, and Governance (ESG) principles into its operations, reinforcing its commitment to sustainability and social responsibility. The VISTA CNY Eye Carnival is part of the company’s broader ESG initiatives, which have earned multiple ESG Awards and BCorp certification—a designation for businesses meeting high social and environmental performance standards.

In 2025, VISTA will collaborate with Tzu Chi Malaysia to offer free cataract surgeries for 100 individuals from poor and underserved communities, reinforcing its commitment to making quality eye care accessible to all.

In addition, VISTA Eye Specialist has recently been honored in the Newsweek Asia Top Private Hospitals 2025 rankings, a testament to its dedication to world-class eye care and patient-centered services.

Gratitude to Our Partners

VISTA extends its sincere gratitude to its collaborating partners, including AbbVie, Johnson & Johnson Vision, Qualitas Health, Staar Surgical, Transmedic, OK Pharmacy, and Ziemer, whose support has been instrumental in making this event possible. Their commitment to advancing eye health aligns with VISTA’s mission to create a healthier and more visually vibrant future for all Malaysians.

Join the Movement for Clear Vision & Purpose

Mark your calendars! The VISTA CNY Eye Carnival 2025 will be happening across multiple locations over two weekends:

14–16 Feb 2025
Puchong, Cheras, Kajang, Ipoh Falim, Penang Straits Residences, Johor Bahru Sutera Utama

21–23 Feb 2025
Petaling Jaya The Curve, Klang, Kepong, Ipoh Bond Square, Air Itam, Johor Bahru Mount Austin

With an increasing number of people living to 100 years and beyond, VISTA believes that restoring clear vision enables individuals to fully embrace their golden years and live life to the fullest.

About VISTA Eye Specialist

A member of Qualitas Health Group, VISTA has been Malaysia’s leading provider of eye care services since 1999. Specializing in cataract and refractive surgeries, VISTA serves thousands of patients annually. Known for its innovative technology, exceptional care, and expert team, VISTA is recognized as the gold standard in eye health across the region.

References

  1. Trading Economics. Malaysia Life Expectancy Data. Retrieved from https://tradingeconomics.com/malaysia/life-expectancy-at-birth-total-years-wb-data.html
  2. PLOS One. Prevalence of Cataract in Malaysia. Retrieved from https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0198799
  3. E-MJM. Risk Factors of Diabetic Retinopathy in Malaysia. Retrieved from https://www.e-mjm.org/2006/v61n4/Risk_Factors_Diabetic_Retinopathy.pdf
  4. LENS Monash. Tackling the Diabetes Epidemic in Malaysia. Retrieved from https://lens.monash.edu/%40medicine-health/2024/11/14/1387170/tackling-the-diabetes-epidemic-in-malaysia-challenges-and-interventions
  5. MOH Malaysia. Annual Eye Examination Guidelines. Retrieved from https://www.moh.gov.my/moh/resources/auto%20download%20images/587f12b24947e.pd

 

Arcadium Lithium Receives All Required Regulatory Approvals Globally to Close Acquisition by Rio Tinto and Announces Court Hearing Date

PHILADELPHIA and PERTH, Australia, Feb. 14, 2025 /PRNewswire/ — Arcadium Lithium plc (NYSE: ALTM, ASX: LTM, “Arcadium Lithium”), a leading global lithium chemicals producer, has now received all required pre-closing regulatory approvals in connection with the proposed acquisition of Arcadium Lithium by Rio Tinto (the “Transaction” previously announced on October 9, 2024).  This includes merger control clearance being satisfied or waived in Australia, Canada, China, Japan, South Korea, the United Kingdom and the United States (Hart-Scott-Rodino Antitrust Improvements Act of 1976), as well as investment screening approval being satisfied in Australia, Canada, Italy, the United Kingdom and the United States (CFIUS).

The sanction hearing for the Royal Court of Jersey (the “Court”) to hear Arcadium Lithium’s application to sanction the scheme of arrangement under Part 18A of the Companies (Jersey) Law 1991 has been set on March 5, 2025 at 5:00 a.m. EST (9:00 p.m. AEDT), with closing of the Transaction expected to occur shortly thereafter on March 6, 2025.

Arcadium Lithium shareholders are entitled to attend and be heard at the Court hearing, either in person or through a Jersey advocate, to support or oppose the Scheme.  The Court’s address is Royal Court House, Royal Square, St Helier, Jersey JE1 1JG and its telephone number is +44 1534 441 300. Arcadium Lithium shareholders may also submit written statements regarding the Scheme for the Court’s consideration.  Such statements can be made either: (i) by email sent to ArcadiumScheme@ogier.com; or (ii) in writing, addressed to Arcadium Scheme Correspondence, c/o Ogier (Jersey) LLP, 3rd Floor, 44 Esplanade, St Helier, Jersey, JE4 9WG.

In connection with completion of the Transaction, Arcadium’s shares and CHESS Depositary Receipts (CDIs) will be delisted from the New York Stock Exchange (NYSE) and the Australian Securities Exchange (ASX) respectively.

For more information, please visit: https://ir.arcadiumlithium.com.

Arcadium Lithium Contacts

Investors:
Daniel Rosen +1 215 299 6208
daniel.rosen@arcadiumlithium.com  

Phoebe Lee +61 413 557 780
phoebe.lee@arcadiumlithium.com   

Media:
Karen Vizental +54 9 114 414 4702
karen.vizental@arcadiumlithium.com  

About Arcadium Lithium 
Arcadium Lithium is a leading global lithium chemicals producer committed to safely and responsibly harnessing the power of lithium to improve people’s lives and accelerate the transition to a clean energy future. We collaborate with our customers to drive innovation and power a more sustainable world in which lithium enables exciting possibilities for renewable energy, electric transportation and modern life.  Arcadium Lithium is vertically integrated, with industry-leading capabilities across lithium extraction processes, including hard-rock mining, conventional brine extraction and direct lithium extraction (DLE), and in lithium chemicals manufacturing for high performance applications. We have operations around the world, with facilities and projects in Argentina, Australia, Canada, China, Japan, the United Kingdom and the United States. For more information, please visit us at www.ArcadiumLithium.com.

Important Information and Legal Disclaimer:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this news release are forward-looking statements. In some cases, we have identified forward-looking statements by such words or phrases as “will likely result,” “is confident that,” “expect,” “expects,” “should,” “could,” “may,” “will continue to,” “believe,” “believes,” “anticipates,” “predicts,” “forecasts,” “estimates,” “projects,” “potential,” “intends” or similar expressions identifying “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words and phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for Arcadium Lithium based on currently available information. There are important factors that could cause Arcadium Lithium’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including the completion of the transaction on anticipated terms and timing, including obtaining required regulatory approvals, and the satisfaction of other conditions to the completion of the transaction; potential litigation relating to the transaction that could be instituted by or against Arcadium Lithium or its affiliates, directors or officers, including the effects of any outcomes related thereto; the risk that disruptions from the transaction will harm Arcadium Lithium’s business, including current plans and operations; the ability of Arcadium Lithium to retain and hire key personnel; potential adverse reactions or changes to business or governmental relationships resulting from the announcement or completion of the transaction; certain restrictions during the pendency of the transaction that may impact Arcadium Lithium’s ability to pursue certain business opportunities or strategic transactions; significant transaction costs associated with the transaction; the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the occurrence of any event, change or other circumstance that could give rise to the termination of the transaction, including in circumstances requiring Arcadium Lithium to pay a termination fee or other expenses; competitive responses to the transaction; the supply and demand in the market for our products as well as pricing for lithium and high-performance lithium compounds; our ability to realize the anticipated benefits of the integration of the businesses of Livent and Allkem or of any future acquisitions; our ability to acquire or develop additional reserves that are economically viable; the existence, availability and profitability of mineral resources and mineral and ore reserves; the success of our production expansion efforts, research and development efforts and the development of our facilities; our ability to retain existing customers; the competition that we face in our business; the development and adoption of new battery technologies; additional funding or capital that may be required for our operations and expansion plans; political, financial and operational risks that our lithium extraction and production operations, particularly in Argentina, expose us to; physical and other risks that our operations and suppliers are subject to; our ability to satisfy customer qualification processes or customer or government quality standards; global economic conditions, including inflation, fluctuations in the price of energy and certain raw materials; the ability of our joint ventures, affiliated entities and contract manufacturers to operate according to their business plans and to fulfill their obligations; severe weather events and the effects of climate change; extensive and dynamic environmental and other laws and regulations; our ability to obtain and comply with required licenses, permits and other approvals; and other factors described under the caption entitled “Risk Factors” in Arcadium Lithium’s 2023 Form 10-K filed with the SEC on February 29, 2024, as well as Arcadium Lithium’s other SEC filings and public communications. Although Arcadium Lithium believes the expectations reflected in the forward-looking statements are reasonable, Arcadium Lithium cannot guarantee future results, level of activity, performance or achievements. Moreover, neither Arcadium Lithium nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Arcadium Lithium is under no duty to update any of these forward-looking statements after the date of this news release to conform its prior statements to actual results or revised expectations.

Logo – https://laotiantimes.com/wp-content/uploads/2025/02/arcadium_lithium_horizontal_logo-1.jpg 

Arcadium Lithium Receives All Required Regulatory Approvals Globally to Close Acquisition by Rio Tinto and Announces Court Hearing Date

PHILADELPHIA and PERTH, Australia, Feb. 14, 2025 /PRNewswire/ — Arcadium Lithium plc (NYSE: ALTM, ASX: LTM, “Arcadium Lithium”), a leading global lithium chemicals producer, has now received all required pre-closing regulatory approvals in connection with the proposed acquisition of Arcadium Lithium by Rio Tinto (the “Transaction” previously announced on October 9, 2024).  This includes merger control clearance being satisfied or waived in Australia, Canada, China, Japan, South Korea, the United Kingdom and the United States (Hart-Scott-Rodino Antitrust Improvements Act of 1976), as well as investment screening approval being satisfied in Australia, Canada, Italy, the United Kingdom and the United States (CFIUS).

The sanction hearing for the Royal Court of Jersey (the “Court”) to hear Arcadium Lithium’s application to sanction the scheme of arrangement under Part 18A of the Companies (Jersey) Law 1991 has been set on March 5, 2025 at 5:00 a.m. EST (9:00 p.m. AEDT), with closing of the Transaction expected to occur shortly thereafter on March 6, 2025.

Arcadium Lithium shareholders are entitled to attend and be heard at the Court hearing, either in person or through a Jersey advocate, to support or oppose the Scheme.  The Court’s address is Royal Court House, Royal Square, St Helier, Jersey JE1 1JG and its telephone number is +44 1534 441 300. Arcadium Lithium shareholders may also submit written statements regarding the Scheme for the Court’s consideration.  Such statements can be made either: (i) by email sent to ArcadiumScheme@ogier.com; or (ii) in writing, addressed to Arcadium Scheme Correspondence, c/o Ogier (Jersey) LLP, 3rd Floor, 44 Esplanade, St Helier, Jersey, JE4 9WG.

In connection with completion of the Transaction, Arcadium’s shares and CHESS Depositary Receipts (CDIs) will be delisted from the New York Stock Exchange (NYSE) and the Australian Securities Exchange (ASX) respectively.

For more information, please visit: https://ir.arcadiumlithium.com.

Arcadium Lithium Contacts

Investors:
Daniel Rosen +1 215 299 6208
daniel.rosen@arcadiumlithium.com  

Phoebe Lee +61 413 557 780
phoebe.lee@arcadiumlithium.com   

Media:
Karen Vizental +54 9 114 414 4702
karen.vizental@arcadiumlithium.com  

About Arcadium Lithium 
Arcadium Lithium is a leading global lithium chemicals producer committed to safely and responsibly harnessing the power of lithium to improve people’s lives and accelerate the transition to a clean energy future. We collaborate with our customers to drive innovation and power a more sustainable world in which lithium enables exciting possibilities for renewable energy, electric transportation and modern life.  Arcadium Lithium is vertically integrated, with industry-leading capabilities across lithium extraction processes, including hard-rock mining, conventional brine extraction and direct lithium extraction (DLE), and in lithium chemicals manufacturing for high performance applications. We have operations around the world, with facilities and projects in Argentina, Australia, Canada, China, Japan, the United Kingdom and the United States. For more information, please visit us at www.ArcadiumLithium.com.

Important Information and Legal Disclaimer:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this news release are forward-looking statements. In some cases, we have identified forward-looking statements by such words or phrases as “will likely result,” “is confident that,” “expect,” “expects,” “should,” “could,” “may,” “will continue to,” “believe,” “believes,” “anticipates,” “predicts,” “forecasts,” “estimates,” “projects,” “potential,” “intends” or similar expressions identifying “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words and phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for Arcadium Lithium based on currently available information. There are important factors that could cause Arcadium Lithium’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including the completion of the transaction on anticipated terms and timing, including obtaining required regulatory approvals, and the satisfaction of other conditions to the completion of the transaction; potential litigation relating to the transaction that could be instituted by or against Arcadium Lithium or its affiliates, directors or officers, including the effects of any outcomes related thereto; the risk that disruptions from the transaction will harm Arcadium Lithium’s business, including current plans and operations; the ability of Arcadium Lithium to retain and hire key personnel; potential adverse reactions or changes to business or governmental relationships resulting from the announcement or completion of the transaction; certain restrictions during the pendency of the transaction that may impact Arcadium Lithium’s ability to pursue certain business opportunities or strategic transactions; significant transaction costs associated with the transaction; the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the occurrence of any event, change or other circumstance that could give rise to the termination of the transaction, including in circumstances requiring Arcadium Lithium to pay a termination fee or other expenses; competitive responses to the transaction; the supply and demand in the market for our products as well as pricing for lithium and high-performance lithium compounds; our ability to realize the anticipated benefits of the integration of the businesses of Livent and Allkem or of any future acquisitions; our ability to acquire or develop additional reserves that are economically viable; the existence, availability and profitability of mineral resources and mineral and ore reserves; the success of our production expansion efforts, research and development efforts and the development of our facilities; our ability to retain existing customers; the competition that we face in our business; the development and adoption of new battery technologies; additional funding or capital that may be required for our operations and expansion plans; political, financial and operational risks that our lithium extraction and production operations, particularly in Argentina, expose us to; physical and other risks that our operations and suppliers are subject to; our ability to satisfy customer qualification processes or customer or government quality standards; global economic conditions, including inflation, fluctuations in the price of energy and certain raw materials; the ability of our joint ventures, affiliated entities and contract manufacturers to operate according to their business plans and to fulfill their obligations; severe weather events and the effects of climate change; extensive and dynamic environmental and other laws and regulations; our ability to obtain and comply with required licenses, permits and other approvals; and other factors described under the caption entitled “Risk Factors” in Arcadium Lithium’s 2023 Form 10-K filed with the SEC on February 29, 2024, as well as Arcadium Lithium’s other SEC filings and public communications. Although Arcadium Lithium believes the expectations reflected in the forward-looking statements are reasonable, Arcadium Lithium cannot guarantee future results, level of activity, performance or achievements. Moreover, neither Arcadium Lithium nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Arcadium Lithium is under no duty to update any of these forward-looking statements after the date of this news release to conform its prior statements to actual results or revised expectations.

Logo – https://laotiantimes.com/wp-content/uploads/2025/02/arcadium_lithium_horizontal_logo-1.jpg 

An independent third-party performance assessment confirms that the Aquarius AQ 150 engine demonstrates 25% higher efficiency than the world’s leading engines, operates on multiple fuel types, and is significantly lighter than existing alternatives

As a reminder, Aquarius’ innovative systems generate and supply clean electricity, designed to enable ultra-fast charging for electric vehicles in the rapidly growing EV market. Aquarius’ systems are smaller and more efficient than existing market solutions and do not depend on the power grid.

According to Gal Fridman, CEO of Aquarius: “This report unequivocally proves that Aquarius has the right solution at the right time in terms of structure, efficiency, and quality. Aquarius continues to lead the revolution in innovative engines and solidify its position in the technology market. With groundbreaking performance, operational flexibility, and a significant competitive advantage, the company anticipates growing interest in AQ engines from various industries.”

TEL AVIV, Israel, Feb. 14, 2025 /PRNewswire/ — Aquarius Engines (TASE: AQUA) is pleased to announce that it has received a performance assessment report for the AQ 150 engine, conducted by BTD (Breuer Technical Development), an independent third-party expert. The report, based on technological validation testing at an external engineering service company, confirms that the Aquarius Engine offers substantial advantages in size, weight, efficiency, and multi-fuel capability.

In the picture: Gal Friedman, CEO and founder of Aquarius Engines, together with the engine developed by the company.
In the picture: Gal Friedman, CEO and founder of Aquarius Engines, together with the engine developed by the company.

Key Findings:

  • The company has begun producing the first units of the Aquarius engine, the AQ dr engine, the first of its kind in the world.
  • The engine concept is modular. From the 6-cylinder engine, derivatives such as a single cylinder or 3 cylinders can be built.
  • The engine has been tested running on LPG in a single-cylinder configuration, with measurements used for simulations across other models.
  • With minimal modifications, the engine is expected to operate on hydrogen and CNG as well.
  • In a six-cylinder configuration, at 3,000 RPM, the engine is projected to achieve an efficiency of 40%.
  • The Aquarius Engine is remarkably lightweight and compact compared to similar engines from leading global manufacturers.
  • When compared to the four leading engine manufacturers worldwide, the Aquarius Engine demonstrates 25% greater efficiency than the best-performing engine on the market.
  • BTD confirms that Aquarius holds unique and essential innovations that fill significant gaps in the market.

It is important to note that the forecasts regarding engine performance and commercial implementation are based on current data but are subject to external factors beyond the company’s control and may change.

The company will continue to update on developments.

Contact:
odedm@aquariusengines.com 

An independent third-party performance assessment confirms that the Aquarius AQ 150 engine demonstrates 25% higher efficiency than the world’s leading engines, operates on multiple fuel types, and is significantly lighter than existing alternatives

As a reminder, Aquarius’ innovative systems generate and supply clean electricity, designed to enable ultra-fast charging for electric vehicles in the rapidly growing EV market. Aquarius’ systems are smaller and more efficient than existing market solutions and do not depend on the power grid.

According to Gal Fridman, CEO of Aquarius: “This report unequivocally proves that Aquarius has the right solution at the right time in terms of structure, efficiency, and quality. Aquarius continues to lead the revolution in innovative engines and solidify its position in the technology market. With groundbreaking performance, operational flexibility, and a significant competitive advantage, the company anticipates growing interest in AQ engines from various industries.”

TEL AVIV, Israel, Feb. 14, 2025 /PRNewswire/ — Aquarius Engines (TASE: AQUA) is pleased to announce that it has received a performance assessment report for the AQ 150 engine, conducted by BTD (Breuer Technical Development), an independent third-party expert. The report, based on technological validation testing at an external engineering service company, confirms that the Aquarius Engine offers substantial advantages in size, weight, efficiency, and multi-fuel capability.

 

In the picture: Gal Friedman, CEO and founder of Aquarius Engines, together with the engine developed by the company.
In the picture: Gal Friedman, CEO and founder of Aquarius Engines, together with the engine developed by the company.

 

Key Findings:

  • The company has begun producing the first units of the Aquarius engine, the AQ dr engine, the first of its kind in the world.
  • The engine concept is modular. From the 6-cylinder engine, derivatives such as a single cylinder or 3 cylinders can be built.
  • The engine has been tested running on LPG in a single-cylinder configuration, with measurements used for simulations across other models.
  • With minimal modifications, the engine is expected to operate on hydrogen and CNG as well.
  • In a six-cylinder configuration, at 3,000 RPM, the engine is projected to achieve an efficiency of 40%.
  • The Aquarius Engine is remarkably lightweight and compact compared to similar engines from leading global manufacturers.
  • When compared to the four leading engine manufacturers worldwide, the Aquarius Engine demonstrates 25% greater efficiency than the best-performing engine on the market.
  • BTD confirms that Aquarius holds unique and essential innovations that fill significant gaps in the market.

It is important to note that the forecasts regarding engine performance and commercial implementation are based on current data but are subject to external factors beyond the company’s control and may change.

The company will continue to update on developments.

Photo: https://laotiantimes.com/wp-content/uploads/2025/02/aquarius_engines-1.jpg

Contact:
odedm@aquariusengines.com 

Bellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc.

SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ — Bellevue Life Sciences Acquisition Corp. (“BLAC”) announced today the approval of each of the proposals presented at the special meeting of its stockholders (the “Special Meeting”) held today, including the proposal for the business combination with OSR Holdings Co., Ltd. (the “Transaction”).  BLAC expects the Transaction to close following receipt of foreign investment approval from the Industrial Bank of Korea, which is expected on February 14, 2025. 

Following the Special Meeting, BLAC filed its Amended and Restated Certificate of Incorporation as approved by the stockholders with the Delaware Secretary of State and has changed its name to OSR Holdings, Inc. (“OSR Holdings”).  Assuming the closing of the Transaction occurs on February 14, 2025, the common stock and warrants of OSR Holdings will begin trading on the Nasdaq Stock Market LLC on February 18, 2025 under the ticker symbols “OSRH” and “OSRHW,” respectively.  In connection with the Special Meeting, 57,821 shares of BLAC Common Stock were tendered for redemption.

Following the Transaction, OSR Holdings will own approximately 67% of the outstanding stock of OSR Holdings Co., Ltd. (“OSR”) and OSR stockholders holding an additional 22% of the outstanding OSR shares have entered into agreements with OSR Holdings providing for the acquisition by OSR Holdings of such shares via put/call provisions commencing in 2026.

Kuk Hyoun Hwang, President and CEO of OSR Holdings, expressed enthusiasm about the Transaction, stating, “The closing will mark a significant achievement and step forward while remaining true to our foundational business strategy as a global Hub-and-Spoke group of healthcare companies.  We are excited about the opportunities this will create for OSR Holdings by leveraging momentum from the completion of the business combination to help advance and grow our subsidiaries and overall drug pipelines.”

“This achievement is a testament to the dedication of our team and their belief in the strength of our vision. We look forward to executing on our corporate strategy to create long-term value to our subsidiary founders, shareholders and investors, and our employees,” said Sang Hoon Kim, CEO of OSR.

Upon the closing of the Transaction, OSR Holdings will continue its business operations in the US, Europe and South Korea. The company’s current portfolio of subsidiaries includes a Phase 2 clinical stage company developing immunotherapies for oncology indications, an early clinical stage company developing disease modifying therapies aimed to address several age-related and other degenerative diseases, and a medical device distributions company.

About OSR Holdings, Inc.

OSR Holdings (formerly Bellevue Life Sciences Acquisition Corp.) was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

About OSR Holdings Co., Ltd.

OSR is a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. OSR aims to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Its current operating businesses (through three wholly-owned subsidiaries) include (i) developing oral immunotherapies for the treatment of cancer, (ii) developing design-augmented biologics for age-related and other degenerative diseases and (iii) neurovascular intervention medical device and systems distribution in Korea. OSR’s vision is to acquire and operate a portfolio of innovative health-care related companies globally.

Forward Looking Statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “goal,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding expectations and timing related to the execution of OSR’s mission to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. These forward-looking statements are based on information available to us as of the date of this communication and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve known and unknown risks, uncertainties and other factors, which may be beyond our control.

These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of OSR Holdings’ and OSR’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of OSR Holdings and OSR. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about OSR that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties, include risks related to the receipt of regulatory approval necessary for closing of the Transaction, OSR’s ability to execute on its strategy; regulatory uncertainties; the potential need for financing to sustain OSR Holdings; market, financial, political and legal conditions; the effects of competition; changes in applicable laws or regulations; and the outcome of any government and regulatory proceedings, investigations and inquiries. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by the forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this communication. We anticipate that subsequent events and developments will cause our assessments to change. However, while we may elect to update these forward-looking statements at some point in the future, OSR Holdings and OSR specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing OSR Holdings’ and OSR’s assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Additional information concerning certain of these risk factors is contained in BLAC’s most recent filings with the U.S. Securities and Exchange Commission, including under the section entitled “Risk Factors” in the prospectus filed on January 31, 2025 by BLAC and other documents filed by BLAC, or to be filed by OSR Holdings, with the SEC.

Media Contact

Tae Min Lee
OSR Holdings Co., Ltd.
Analyst
taemin.lee@osr-holdings.com 

Investor Contact

Kuk Hyoun Hwang
OSR Holdings, Inc.
Chairman & CEO
peter.hwang@osr-holdings.com 

 

 

 

IFF Announces Launch of New IFF.com

NEW YORK, Feb. 14, 2025 /PRNewswire/ — IFF (NYSE: IFF) today unveiled its newly redesigned corporate website, www.iff.com, marking a significant leap in scale, performance and commitment to top-tier digital experiences. The revamped site offers a visually captivating and engaging journey, highlighting IFF’s leadership and the value it delivers across all the markets it serves.

“The IFF site represents the full breadth of our portfolio and the value we offer through our technology and innovation,” said Deb Borg, executive vice president and chief communications, human resources, and diversity & inclusion officer. “It is a powerful tool for increasing our brand recognition, strengthening our customer relationships and attracting world-class talent.”

The new website features improved navigation, fresh content, enhanced lead-generation tools, and CRM strategies all within a responsive and modern design. Visitors can easily access key information and resources. The new comprehensive media center provides diverse perspectives on the company and easy access to business-specific content. Additionally, an expanded sustainability hub—along with careers, history, insights, and science sections—offers deeper context about the company, showcasing its expertise. The new user experience reflects visitors’ needs, enabling a customized journey throughout the site.

“The IFF.com redesign is a true expression of our brand,” said Paulina Heinkel, vice president of corporate communications. “Visitors will enjoy a unique experience, gaining a clear understanding of our culture and the interconnectivity of our products across various businesses. It truly exemplifies our company’s purpose of making joy through science, creativity and heart.”

For more information, and to experience the new website, visit iff.com.

###

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.comLinkedInInstagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.